Volume 10, Number 4 (May/Jun 2019)

Editorial

American Society of Clinical Oncology Reports on Clinical Cancer Advances

The American Society of Clinical Oncology recently released its Clinical Cancer Advances 2019 report on the progress against cancer. The report brings attention to the most important clinical research advances of the past year and examin...

May 21, 2019

Original Research

Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis

Abstract Cabozantinib inhibits tyrosine kinase activity at the MET, AXL, and VEGF receptors and is approved for front-line therapy in metastatic clear cell renal cell carcinoma. Little off-protocol data exist on tolerability and respons...

May 21, 2019

Original Research

Diversity Awareness and Documentation Practices Among Oncology Advanced Practice Providers

Abstract Advanced practice providers (APPs) care for widely diverse populations. The Institute of Medicine (IOM) states that bias, prejudice, and stereotyping by a health-care provider may contribute to disparities, which are associated...

May 21, 2019

Review Article

Cardiac Toxicity and Anthracyclines: Mechanism, Interventions, and the Trouble With Troponin

As cancer survivorship increases, clinicians need to become educated regarding the long-term effect of cancer treatments. Cancer therapeutics–related cardiac dysfunction (CTRCD) is one such sequela that contributes to significant morbidi...

May 21, 2019

Review Article

The Advanced Practice Provider Perspective: Treating Patients With Immuno-Oncology Combination Therapy Across Tumor Types

Abstract A number of immune checkpoint inhibitors (ICIs) have been approved by the U.S. Food and Drug Administration (FDA) as immuno-oncology (IO) monotherapy for multiple solid and hematologic tumor types across various lines of therap...

May 21, 2019

Grand Rounds

Breast Cancer in the Transgender Population

Case Study ES is a 41-year-old transgender male who presented to medical oncology as a referral from surgical oncology for T2N0M0 right breast cancer. At that time, he was receiving weekly testosterone injections intramuscularly at 0.25...

May 21, 2019

Translating Research Into Practice

Secondary Analysis Research

Abstract In secondary data analysis (SDA) studies, investigators use data collected by other researchers to address different questions. Like primary data researchers, SDA investigators must be knowledgeable about their research area to...

May 21, 2019

Prescriber's Corner

Rucaparib and Niraparib in Advanced Ovarian Cancer

Abstract Rucaparib and niraparib are two of the newest U.S. Food and Drug Administration–approved PARP inhibitors, joining olaparib with indications in ovarian cancer. Both drugs have led to meaningful responses when used as monotherapy...

May 21, 2019